Overview

AL Amyloidosis and Anti-CD38-Daratunumab

Status:
COMPLETED
Trial end date:
2024-02-02
Target enrollment:
Participant gender:
Summary
AL Amyloidosis and anti-CD38
Phase:
NA
Details
Lead Sponsor:
University of Turin, Italy
Treatments:
daratumumab